BPC-157

BPC-157 (Body Protection Compound) is a pentadecapeptide (15 amino acids). The HEIVE catalog describes it as: A synthetic fragment of a protein found in human gastric juice, studied almost entirely in rodents for accelerated soft-tissue healing. It is also known as BPC 157, Body Protection Compound 157 and Pentadecapeptide BPC 157.

HEIVE groups BPC-157 under inflammation, tissue repair, gut healing, training recovery and nerve repair. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for BPC-157 under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval.

• FDA product data (October 6, 2026)
• FDA compounding safety information

The HEIVE editorial risk summary for BPC-157 lists: Injection-site irritation; occasional light-headedness in the first week. Longer-term concerns: Unknown. No human study has run past 12 weeks. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

BPC-157 has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for BPC-157: 250–500 mcg once daily, near the injury site where practical. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies BPC-157 as mainly preclinical. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists oral, topical or a nasal form for BPC-157. A listed form is not evidence of an approved or effective treatment. Nasal forms are listed in the source catalog; this does not establish approval, efficacy or equivalent absorption. HEIVE injection calculations do not apply to nasal forms.

Preparation of BPC-157 depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for BPC-157 depends on the specific formulation (injectable, oral, topical and nasal in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for BPC-157: No tolerance reported. No withdrawal syndrome described. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

BPC-157 and TB-500 share the catalog categories inflammation, tissue repair and training recovery. BPC-157: A synthetic fragment of a protein found in human gastric juice, studied almost entirely in rodents for accelerated soft-tissue healing. TB-500: An actin-binding fragment associated with cell migration and blood-vessel formation in injured tissue. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View TB-500

The HEIVE editorial summary highlights: Rodent work repeatedly shows gut-brain effects — reduced anxiety behaviour — that nobody was looking for. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.